Anti-DR4抗体[DR-4-02] - Low endotoxin, Azide free (ab14738)


  • 产品名称Anti-DR4抗体[DR-4-02] - Low endotoxin, Azide free
    参阅全部 DR4 一抗
  • 描述
    小鼠单克隆抗体[DR-4-02] to DR4 - Low endotoxin, Azide free
  • 经测试应用适用于: IP, Functional Studies, Flow Cyt, ICC/IFmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Fusion protein (Human). Fusion protein containing the extracellular part of DR4 and the constant part of the heavy chain of the human IgG1.



Our Abpromise guarantee covers the use of ab14738 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
Functional Studies
Flow Cyt
  • 应用说明Flow Cyt: Use at a concentration of 3 - 5 µg/ml.
    FuncS: Use at an assay dependent dilution.Soluble antibody blocks DR4 receptor against TRAIL-induced apoptosis. Plastic-immobilized antibody induces apoptosis in sensitive cells.
    Recommended dilution of antibody: 2-3 µg/ml in cultivation medium
    Final concentration of TRAIL: 20-200 ng/ml
    Application note: It is recommended to add the antibody 15 min before addition of TRAIL.

    ICC/IF: Use at an assay dependent dilution.
    IP: Use at an assay dependent dilution.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • 靶标

    • 功能Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
    • 组织特异性Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
    • 序列相似性Contains 1 death domain.
      Contains 3 TNFR-Cys repeats.
    • 细胞定位Membrane.
    • Information by UniProt
    • 数据库链接
    • 别名
      • Apo2 antibody
      • CD261 antibody
      • Cytotoxic TRAIL receptor antibody
      • Death receptor 4 antibody
      • DR4 antibody
      • NF related apoptosis-inducing ligand receptor 1 antibody
      • TNF-related apoptosis-inducing ligand receptor 1 antibody
      • TNFRSF10A antibody
      • TR10A_HUMAN antibody
      • TRAIL receptor 1 antibody
      • TRAIL-R1 antibody
      • TRAILR1 antibody
      • Tumor necrosis factor receptor superfamily member 10A antibody
      see all

    Anti-DR4 antibody [DR-4-02] - Low endotoxin, Azide free 图像

    • Flow Cytometry analysis of DR4 expression on the surface of hematopoietic cell lines. Cells were stained with purified anti-DR4 antibodies (ab14738) followed by Goat anti-mouse IgG PE. Histograms: Red - Goat anti-mouse IgG PE (no primary antibody) Black - anti-DR4 comparative antibody Blue and Green - anti-DR4 (ab14738:DR-4-02) in duplicate staining
    • Immunofluorescence staining (confocal microscopy) of HeLa human cervix carcinoma cell line transfected with DR4 expression plasmid using anti-human DR4 (ab14738:DR-4-02).

    Anti-DR4 antibody [DR-4-02] - Low endotoxin, Azide free (ab14738)参考文献

    This product has been referenced in:
    • Passante E  et al. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ 20:1521-31 (2013). Read more (PubMed: 23933815) »
    • Franzen CA  et al. Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 7:1045-55 (2009). Read more (PubMed: 19584265) »

    See all 2 Publications for this product

    Product Wall

    Vielen Dank für Ihren Anruf.
    Ich habe nachgefragt ob und wie die Spezifität der folgenden Antikörper getestet wurde:
    Dieser Antikörper wurde nicht experimentell auf die Kreuzreaktion mit anderen Trail Rezeptoren getestet. Ich k...

    Read More

    We can confirm that ab14738 is DR4 specific (at least as far as tested on transfectants). Please do not hesitate to contact us again if you need further information,

    The protocol I sent is correct- this is how the originator uses its antibody. However, I think the originators do not optimally titrate the antibody since they do not worry about the load (unlimited access of antibody), so you may find you will be able...

    Read More

    Thank you for your enquiry. Here is the protocol recommended for induction experiments: The antibody (at a final concentration 100 ug/ml) is spread onto the surface of plastic dish just to cover it (layer about 1-2 mm; e.g. 50 ul into a well of 96-...

    Read More